LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Bought by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lifted its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 19.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,794 shares of the medical instruments supplier's stock after acquiring an additional 3,852 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.11% of LeMaitre Vascular worth $1,996,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. New York State Teachers Retirement System boosted its position in LeMaitre Vascular by 1.2% during the 4th quarter. New York State Teachers Retirement System now owns 8,189 shares of the medical instruments supplier's stock worth $755,000 after acquiring an additional 100 shares during the last quarter. Flputnam Investment Management Co. grew its position in shares of LeMaitre Vascular by 3.6% in the fourth quarter. Flputnam Investment Management Co. now owns 2,923 shares of the medical instruments supplier's stock valued at $269,000 after purchasing an additional 102 shares during the last quarter. Norden Group LLC increased its position in LeMaitre Vascular by 4.5% during the 4th quarter. Norden Group LLC now owns 2,371 shares of the medical instruments supplier's stock worth $218,000 after buying an additional 103 shares during the period. Blue Barn Wealth LLC boosted its holdings in LeMaitre Vascular by 4.4% in the 4th quarter. Blue Barn Wealth LLC now owns 2,485 shares of the medical instruments supplier's stock valued at $229,000 after purchasing an additional 104 shares during the period. Finally, Shaker Investments LLC OH increased its stake in LeMaitre Vascular by 0.8% during the 4th quarter. Shaker Investments LLC OH now owns 13,948 shares of the medical instruments supplier's stock worth $1,285,000 after acquiring an additional 112 shares during the period. 84.64% of the stock is owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 76,868 shares of the stock in a transaction on Monday, May 19th. The shares were sold at an average price of $85.79, for a total value of $6,594,505.72. Following the transaction, the chief executive officer now directly owns 1,796,783 shares of the company's stock, valued at $154,146,013.57. This trade represents a 4.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 102,009 shares of company stock worth $8,721,836. 9.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have commented on LMAT. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Finally, Lake Street Capital increased their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, LeMaitre Vascular currently has an average rating of "Hold" and an average price target of $97.83.

LeMaitre Vascular Trading Down 1.0%

LMAT traded down $0.81 during midday trading on Monday, reaching $83.32. The company's stock had a trading volume of 97,071 shares, compared to its average volume of 168,453. LeMaitre Vascular, Inc. has a 1 year low of $71.42 and a 1 year high of $109.58. The stock's 50-day moving average is $83.65 and its 200-day moving average is $90.74. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 45.53, a PEG ratio of 2.22 and a beta of 0.83.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. During the same quarter in the previous year, the company earned $0.44 EPS. The business's quarterly revenue was up 12.0% compared to the same quarter last year. As a group, equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.96%. The ex-dividend date of this dividend was Thursday, May 15th. LeMaitre Vascular's payout ratio is currently 40.40%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.